Recent Posts
- Illinois Attorney General Files Lawsuit Against HIV/AIDS Nonprofit
- California Gov. Arnold Schwarzenegger Signs Budget That Cuts $52M From HIV/AIDS Programs
- Efforts Underway In Namibia To Treat Pediatric HIV
- HIV/AIDS Education Project Targeting Pennsylvania Black Women Examined
- Also In Global Health News: Uganda Male Circumcision; Malaria Vaccine; Potential Global Fund Grant In Cambodia; PMTCT Of HIV In Botswana
Random Posts
- Racial HIV Disparities Are An Indictment Of The US Response To The Epidemic
- New HIV Saliva Test Delivers Results In Just 20 Minutes, UK
- Local Events Focus On HIV Testing, Awareness
- Researchers Develop Vaccine Candidate That Is Successful In Blocking Simian Version Of HIV
- Gene Transfer Technology May Lead To HIV Vaccine
- Study Examines 'Elite' Group Of HIV-Positive People Who Appear 'Protected' From Developing AIDS
- New HIV Recommendations To Improve Health, Reduce Infections And Save Lives
- Recent Releases On Global Health
- Terrence Higgins Trust Launches New Group For Gay Men With Hepatitis C And HIV, UK
- Lesotho Government, UNICEF, European Union Launch Pilot Program To Provide Financial Support To AIDS Orphans
Prescription AIDS Drugs
Contact Us
Stem cells containing protective genes may provide permanent control of human immunodeficiency virus (HIV) in infected individuals, according to research presented at the American Society of Gene Therapy 12th Annual Meeting, May 30.
In a landmark study, researchers demonstrated that a hematopoietic stem cell therapy could safely and effectively provide long-lasting control of HIV.
“This study was the first phase II randomized, controlled, double-blind study for cell-delivered HIV gene therapy and the first controlled HIV gene therapy study to show positive impact on viral load and CD4 count,” said Geoff Symonds, PhD, senior research director at Calimmune, Inc. “This study is a major advance in the field and it paves the way for future treatment with this new therapeutic paradigm.”
Seventy-four patients were enrolled in the study’s two treatment arms. There were no serious adverse events reported from the gene therapy.
An estimated 1 million Americans and 35 million individuals worldwide, are infected with HIV, the virus that causes AIDS. Conventional HIV treatments, such as highly active antiretroviral therapy (HAART), are effective at slowing the disease’s progression by controlling the amount of virus in the body. These therapies, however, require a lifelong regimen of medications and are hindered by severe side effects and immense costs.
The American Society of Gene Therapy (ASGT) 12th Annual Meeting is the world’s largest scientific meeting surrounding the latest developments in gene and cell therapy, attended by nearly 2,000 researchers from around the world and featuring 60 scientific presentations.
Source
ASGT
Related posts:
- Gene Transfer Technology May Lead To HIV Vaccine A research team may have broken the impasse that has...
- Gladstone Scientists Identify Key Factor That Controls HIV Latency Scientists at the Gladstone Institutes of Virology and Immunology (GIVI)...
- First Engineered T Cell Receptor Trial Opens With New Cellular Therapy For HIV Researchers at the University of Pennsylvania School of Medicine and...
- New Report Shows 97 Medicines And Vaccines Currently In Development For HIV/AIDS America’s pharmaceutical research and biotechnology companies are testing 97 medicines...
- Directly Observed Antiretroviral Therapy Offers No Benefit Over Self-Administered Treatment For HIV Patients Directly observed antiretroviral therapy-in which a health worker or other...
Related posts brought to you by Yet Another Related Posts Plugin.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.